Citigroup Inc Phathom Pharmaceuticals, Inc. Transaction History

Citigroup Inc

$163 Billion
Q4 2024

A detailed history of Citigroup Inc transactions in Phathom Pharmaceuticals, Inc. stock. As of the latest transaction made, Citigroup Inc holds 44,577 shares of PHAT stock, worth $246,956. This represents 0.0% of its overall portfolio holdings.

Number of Shares

44,577

Previous 31,521 41.42%

Holding current value

$246,956

Previous $569,000 36.56%

% of portfolio

0.0%

Previous 0.0%

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 12, 2025	BUY	$7.45 - $18.94 $97,267 - $247,280	13,056 Added 41.42%	44,577 $361,000
Q3 2024 Nov 12, 2024	BUY	$10.25 - $19.5 $232,316 - $441,967	22,665 Added 255.93%	31,521 $569,000
Q2 2024 Aug 12, 2024	BUY	$8.97 - $12.05 $25,214 - $33,872	2,811 Added 46.5%	8,856 $91,000
Q1 2024 May 10, 2024	BUY	$6.21 - $11.05 $2,459 - $4,375	396 Added 7.01%	6,045 $64,000
Q4 2023 Feb 09, 2024	BUY	$6.99 - $10.71 $12,728 - $19,502	1,821 Added 47.57%	5,649 $51,000
Q3 2023 Nov 09, 2023	SELL	$10.26 - $15.7 $53,926 - $82,519	-5,256 Reduced 57.86%	3,828 $39,000
Q2 2023 Aug 10, 2023	BUY	$7.28 - $14.32 $59,244 - $116,536	8,138 Added 860.25%	9,084 $130,000
Q1 2023 May 11, 2023	SELL	$6.19 - $12.36 $1,151 - $2,298	-186 Reduced 16.43%	946 $6,000
Q4 2022 Feb 09, 2023	SELL	$9.18 - $11.53 $1,055 - $1,325	-115 Reduced 9.22%	1,132 $12,000
Q3 2022 Nov 10, 2022	SELL	$6.46 - $12.11 $8,152 - $15,282	-1,262 Reduced 50.3%	1,247 $14,000
Q2 2022 Aug 10, 2022	BUY	$6.2 - $15.5 $2,560 - $6,401	413 Added 19.7%	2,509 $21,000
Q1 2022 May 12, 2022	SELL	$11.55 - $20.06 $61,850 - $107,421	-5,355 Reduced 71.87%	2,096 $29,000
Q4 2021 Feb 10, 2022	BUY	$17.83 - $33.15 $35,142 - $65,338	1,971 Added 35.97%	7,451 $147,000
Q3 2021 Nov 10, 2021	BUY	$30.69 - $36.83 $168,181 - $201,828	5,480 New	5,480 $176,000

Others Institutions Holding PHAT

# of Institutions

158

Shares Held

68.6M

Call Options Held

52.3K

Put Options Held

635K

View Full List

About Phathom Pharmaceuticals, Inc.

Ticker PHAT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,175,200
Market Cap $217M
Description
Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also develo...

More about PHAT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

News

Stay updated on Citigroup Inc with notifications on news.

Account